Universite Claude Bernard – Lyon1

Centre National De La Recherche Scientifique

Universitè Laval

Institut National De La Sante Et De La Recherche Medicale

Ecole Normale Superieure De Lyon

Les Hospices Civils De Lyon

Centre National De La Recherche Scientifique-cnrs

Hospices Civils De Lyon

Institut National De La Sante Et De La Recherche Medicale (inserm)

University of Dundee

Université Claude Bernard Lyon I

Olivier Terrier

Manuel Rosa-Calatrava

Guy Boivin

Francois Edouard Julien Durupt

Mario Andres Pizzorno

Manuel Melchior Jean-Pierre Rosa Calatrava

Julien Textoris

Jean-Christophe Bourdon

Bruno Lina

Vincent Moules

Claire Nicolas De Lamballerie

Mario Pizzorno

Danielle Françoise Thouvenot

Julia Dubois

Mario-Andres Pizzorno

Blandine Padey

Marie-Eve Hamelin

Marie-Helene Cavanagh

Anaïs Proust

Manuel Rosa-calatrava

Manuel Rosa Calatrava

Francois Durupt

Jean-Pierre Rosa Calatrava Manuel Melchior

Francois Edouard Durupt

Marie-Hélène Cavanagh

François Edouard Julien Durupt

The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.

Combination of diltiazem and viral polymerase inhibitors

The present invention relates to diltiazem for use as an agent for activating the expression of at least one gene encoding a type III interferon, in the prevention and/or treatment of infections by at least one pathogenic microorganism of the epithelia of the respiratory and/or intestinal tracts.

Diltiazem for use in the treatment of microbial infections

The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.

Antiviral compositions for the treatment of infections linked to coronaviruses

The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.

Attenuated virus strain and use thereof as a vaccine

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Antiviral compositions for treating the flu

The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus, characterized in that the production is carried out in the presence of an inhibitor of the interaction between the Mdm2 protein and the p53 protein.

Method for improving the production of influenza viruses and vaccine seeds

A variant phylogenetic group of HPIV-2, more particularly a novel variant phylogenetic sub-group of HPIV-2, and a means for diagnosing HPIV-2 which take into account this novel group and this novel sub-group.

HPIV-2 variants and their medical applications

The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.

Mutant proteins of the F protein of PIV-5 and PIV-2

Growing community of inventors

Lyons, France

Olivier Terrier